Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

a study on Chronic Granulomatous Disease

Summary

Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Morna Dorsey, MD

Description

Summary

This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.

Official Title

A Cross-Sectional, Observational Study of the Prevalence of Adenoviral-Specific Antibodies and Inflammatory Cytokines in Participants With Chronic Granulomatous Disease

Details

In this observational study, blood samples will be collected from adult and pediatric patients with CGD. The level of circulating adenovirus antibodies and inflammatory cytokines will be measured to characterize the prevalence of these markers in this population.

Keywords

Chronic Granulomatous Disease (CGD), CGD, X-CGD, Chronic Granulomatous Disease, Granulomatous Disease, Chronic, Autosomal Recessive Chronic Granulomatous Disease, Granuloma

Eligibility

You can join if…

  • The participant must have been diagnosed with CGD based on the referring physician's confirmation that NADPH oxidase activity is ≤5% (i.e., the percentage of dihydrorhodamine-positive [DHR+] cells is ≤5% by flow cytometry) OR based on confirmed pathogenic mutation in a CGD associated gene (CYBB, CYBA, NCF1, NCF2, NCF4, or CYBC1).
  • The participant or the participant's legally authorized guardian or representative (if applicable) must be capable of giving signed informed consent.
  • The participant (with assistance from the participant's legally authorized guardian/representative or primary caregiver, if applicable) must be capable of complying with the requirements and restrictions listed in the protocol and informed consent form (ICF).

You CAN'T join if...

  • The participant has undergone an allogeneic bone marrow transplant or investigational gene therapy.
  • The participant is unable to comply with the sample collection procedure based on investigator judgment.

Locations

  • UCSF accepting new patients
    San Francisco California 94158 United States
  • Home-based telemedicine accepting new patients
    Sacramento California 95814 United States

Lead Scientist at UCSF

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ensoma
ID
NCT06605378
Study Type
Observational
Participants
Expecting 60 study participants
Last Updated
Contact us about this trial